NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells

Zhu,Ni; Wang,Huafang; Wei,Jieping; Wang,Binsheng; Shan,Wei; Lai,Xiaoyu; Zhao,Yanmin; Yu,Jian; Huang,He

doi:10.3892/mmr.2016.5389

NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells

Authors:
- Ni Zhu
- Huafang Wang
- Jieping Wei
- Binsheng Wang
- Wei Shan
- Xiaoyu Lai
- Yanmin Zhao
- Jian Yu
- He Huang
View Affiliations

Affiliations: Bone Marrow Transplantation Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: June 10, 2016 https://doi.org/10.3892/mmr.2016.5389
Pages: 1351-1356

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone marrow-derived mesenchymal stem cells (BM-MSCs) are pivotal components of the leukemic microenvironment. BM-MSCs have been previously reported to promote the proliferation of leukemic cells. To further understand the molecular mechanisms of BM-MSC-induced proliferation of leukemic cells, the present study co-cultured acute lymphoblastic leukemia (ALL) Reh cells with BM-MSCs. The current study used methods including shRNA, flow cytometry, MTT, reverse transcription-quantitative polymerase chain reaction, ELISA and western blotting. The data of the present study demonstrated that BM‑MSCs promote the proliferation of Reh cells and the NR2F2 mRNA and protein levels were elevated in BM‑MSCs following co‑culture. Additionally, it was demonstrated that shRNA knockdown of NR2F2 inhibited BM‑MSC‑induced proliferation of Reh cells. Furthermore, following downregulation of NR2F2, vascular endothelial growth factor A (VEGFA) secretion by BM‑MSCs was reduced. The present study demonstrated that NR2F2 mediates BM‑MSC‑induced proliferation of Reh cells, partially via regulation of VEGFA. Disrupting microenvironmental support by targeting NR2F2 may be a potential therapeutic strategy for ALL.

View Figures

View References

1	Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D and Kantarjian HM: Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer. 116:1165–1176. 2010. View Article : Google Scholar : PubMed/NCBI
2	Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, et al Medical Research Council: of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 109:944–950. 2007. View Article : Google Scholar
3	Shishido S, Bönig H and Kim YM: Role of integrin alpha4 in drug resistance of leukemia. Front Oncol. 4:992014. View Article : Google Scholar : PubMed/NCBI
4	Clark BR and Keating A: Biology of bone marrow stroma. Ann N Y Acad Sci. 770:70–78. 1995. View Article : Google Scholar : PubMed/NCBI
5	Juarez J, Baraz R, Gaundar S, Bradstock K and Bendall L: Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica. 92:450–459. 2007. View Article : Google Scholar : PubMed/NCBI
6	Gaundar SS, Bradstock KF and Bendall LJ: p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle. 8:2975–2983. 2009. View Article : Google Scholar : PubMed/NCBI
7	Malfuson JV, Boutin L, Clay D, Thépenier C, Desterke C, Torossian F, Guerton B, Anginot A, de Revel T, Lataillade JJ and Le Bousse-Kerdilès MC: SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia. 28:853–864. 2014. View Article : Google Scholar
8	van Dongen JJ, van der Velden VH, Brüggemann M and Orfao A: Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood. 125:3996–4009. 2015. View Article : Google Scholar : PubMed/NCBI
9	Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, et al: The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis. 36(Suppl 1): S160–S183. 2015. View Article : Google Scholar : PubMed/NCBI
10	Pereira FA, Qiu Y, Zhou G, Tsai MJ and Tsai SY: The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev. 13:1037–1049. 1999. View Article : Google Scholar : PubMed/NCBI
11	Xie X, Qin J, Lin SH, Tsai SY and Tsai MJ: Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci USA. 108:14843–14848. 2011. View Article : Google Scholar : PubMed/NCBI
12	Safe S, Jin UH, Hedrick E, Reeder A and Lee SO: Minireview: Role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol. 28:157–172. 2014. View Article : Google Scholar :
13	Yang Y, Mallampati S, Sun B, Zhang J, Kim SB, Lee JS, Gong Y, Cai Z and Sun X: Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett. 333:9–17. 2013. View Article : Google Scholar : PubMed/NCBI
14	Hu K, Gu Y, Lou L, Liu L, Hu Y, Wang B, Luo Y, Shi J, Yu X and Huang H: Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway. J Hematol Oncol. 8:12015. View Article : Google Scholar
15	Beresford MJ, Wilson GD and Makris A: Measuring proliferation in breast cancer: Practicalities and applications. Breast Cancer Res. 8:2162006. View Article : Google Scholar : PubMed/NCBI
16	Li L, Xie X, Qin J, Jeha GS, Saha PK, Yan J, Haueter CM, Chan L, Tsai SY and Tsai MJ: The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. Cell Metab. 9:77–87. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang B, Hu Y, Liu L, Hu K, Tie R, He Y, Fu S, Zhu N, Luo Y, Yu X and Huang H: Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 21:1020–1028. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhang Y, Hu K, Hu Y, Liu L, Wang B and Huang H: Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation. Ann Hematol. 93:1499–1508. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chen X, Qin J, Cheng CM, Tsai MJ and Tsai SY: COUP-TFII is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol. 26:1268–1277. 2012. View Article : Google Scholar : PubMed/NCBI